Monday, 28 August 2017 09:25

Anticoagulation news items. Week commencing 21st August 2017

FDA grants priority review to licensing application for haemophilia drug emicizumab

Reuters Health

Roche said submission is based on positive data from phase 3 study in adolescents/adults with haemophilia A with inhibitors (IHs) and interim phase III results in children. It said ~30% patients develop IHs limiting treatment options and increasing risk of life-threatening bleeds.


NIHR Signal: Drug reduces deaths from bleeding after childbirth

National Institute for Health Research Signal

Expert commentary is provided for an RCT (20,600 women with post-partum haemorrhage) which found that IV tranexamic acid reduced the risk of death from bleeding vs placebo. The challenge is to promptly implement the early use of tranexamic acid into best practice.


Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets. S2TOP-BLEED


A prediction model for major bleeding in patients with a TIA or ischaemic stroke on antiplatelets was developed following review of data from 6 RCTs. Authors claim that the S2TOP-BLEED score had a reasonable external validation but slightly underestimated the major bleeding risk.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: